



NATIONAL QUALITY FORUM

Driving measurable health
improvements together

Memo

August 5, 2020

To: NQF members

From: NQF staff

Re: Cardiovascular, Spring 2020 cycle draft report for review

Background

This report reflects the review of measures in the Cardiovascular project. In the spring 2020 cycle of this project, the 22-person Cardiovascular Standing Committee met in person to review four maintenance measures against NQF's standard evaluation criteria. All four measures were recommended for endorsement.

Recommended Measures:

- **NQF 0066** Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%) (American Heart Association)
- **NQF 0067** Coronary Artery Disease (CAD): Antiplatelet Therapy (American Heart Association)
- **NQF 0076** Optimal Vascular Care (MN Community Measurement)
- **NQF 0290** Median Time to Transfer to Another Facility for Acute Coronary Intervention (Centers for Medicare and Medicaid Services (CMS)/Mathematica)

The Committee requests comments on all measures.

NQF Member and Public Commenting

NQF members and the public are encouraged to provide comments via the online commenting tool on the draft report as a whole, or on the specific measures evaluated by the Cardiovascular Standing Committee.

Please note that commenting concludes on September 3, 2020 at 6:00 pm ET—no exceptions.